C4 Therapeutics Ownership 2024 | Who Owns C4 Therapeutics Now?
Institutional Ownership
113.18%
Insider Ownership
11.75%
Retail Ownership
-24.93%
Institutional Holders
109.00
C4 Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STATE STREET CORP | 13.97% | 0.00% | 7,153,280 | 6,997,907 | 4503.94% | 58,442,298 | Mar 31, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 9.52% | 0.06% | 4,878,000 | - | - | 39,853,260 | Mar 31, 2024 |
| WASATCH ADVISORS LP | 8.45% | 0.18% | 4,328,479 | -2,810,470 | -39.37% | 35,363,673 | Mar 31, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 7.10% | 7.70% | 3,634,662 | 500,266 | 15.96% | 29,695,189 | Mar 31, 2024 |
| COMMODORE CAPITAL LP | 6.66% | 1.86% | 3,410,384 | -389,616 | -10.25% | 27,862,837 | Mar 31, 2024 |
| VANGUARD GROUP INC | 5.70% | 0.00% | 2,920,028 | 920,627 | 46.05% | 23,856,629 | Mar 31, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 4.80% | 1.49% | 2,458,996 | 623,000 | 33.93% | 20,089,997 | Mar 31, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | 4.76% | 0.03% | 2,435,380 | 731,111 | 42.90% | 19,897,055 | Mar 31, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.13% | 0.00% | 2,115,477 | -443,003 | -17.32% | 17,284,000 | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | 3.62% | 0.00% | 1,855,158 | 180,061 | 10.75% | 15,156,641,000 | Mar 31, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.80% | 3.26% | 1,435,931 | 1,435,931 | 100.00% | 11,731,556 | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 2.56% | 0.02% | 1,312,200 | 1,239,500 | 1704.95% | 10,720,674 | Mar 31, 2024 |
| ARROWMARK COLORADO HOLDINGS LLC | 2.52% | 0.12% | 1,291,939 | -845,442 | -39.55% | 10,555,142 | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | 2.50% | 0.00% | 1,281,242 | 1,167,729 | 1028.72% | 10,467,747 | Mar 31, 2024 |
| TCG CROSSOVER MANAGEMENT, LLC | 2.49% | 0.82% | 1,276,574 | - | - | 10,429,610 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 2.29% | 0.02% | 1,171,840 | 1,171,840 | 100.00% | 9,573,933 | Mar 31, 2024 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 2.23% | 0.75% | 1,142,210 | -500,000 | -30.45% | 9,331,856 | Mar 31, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 1.77% | 0.02% | 906,472 | -1,054,887 | -53.78% | 7,405,876 | Mar 31, 2024 |
| BLACKROCK INC. | 1.77% | 0.00% | 905,006 | -898,427 | -49.82% | 7,393,899 | Mar 31, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 1.63% | 0.03% | 833,681 | 833,681 | 100.00% | 6,811,174 | Mar 31, 2024 |
C4 Therapeutics's largest institutional shareholder is STATE STREET CORP, holding 13.97% of the company's total share outstanding, currently valued at $58.44M. The top 10 institutional shareholders own together 68.71% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 7.10% | 7.70% | 3,634,662 | 500,266 | 15.96% | 29,695,189 | Mar 31, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.80% | 3.26% | 1,435,931 | 1,435,931 | 100.00% | 11,731,556 | Mar 31, 2024 |
| COMMODORE CAPITAL LP | 6.66% | 1.86% | 3,410,384 | -389,616 | -10.25% | 27,862,837 | Mar 31, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 4.80% | 1.49% | 2,458,996 | 623,000 | 33.93% | 20,089,997 | Mar 31, 2024 |
| TCG CROSSOVER MANAGEMENT, LLC | 2.49% | 0.82% | 1,276,574 | - | - | 10,429,610 | Mar 31, 2024 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 2.23% | 0.75% | 1,142,210 | -500,000 | -30.45% | 9,331,856 | Mar 31, 2024 |
| ATOM INVESTORS LP | 0.62% | 0.32% | 316,246 | 316,246 | 100.00% | 2,583,730 | Mar 31, 2024 |
| ENTRYPOINT CAPITAL, LLC | 0.06% | 0.21% | 28,516 | 28,516 | 100.00% | 232,976 | Mar 31, 2024 |
| WASATCH ADVISORS LP | 8.45% | 0.18% | 4,328,479 | -2,810,470 | -39.37% | 35,363,673 | Mar 31, 2024 |
| ARROWMARK COLORADO HOLDINGS LLC | 2.52% | 0.12% | 1,291,939 | -845,442 | -39.55% | 10,555,142 | Mar 31, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | 0.19% | 0.10% | 96,964 | 21,170 | 27.93% | 792,000 | Mar 31, 2024 |
| QUEST PARTNERS LLC | 0.13% | 0.09% | 64,001 | 64,001 | 100.00% | 522,888 | Mar 31, 2024 |
| FOX RUN MANAGEMENT, L.L.C. | 0.08% | 0.07% | 41,732 | 41,732 | 100.00% | 340,950 | Mar 31, 2024 |
| ARETE WEALTH ADVISORS, LLC | 0.17% | 0.06% | 85,200 | 13,100 | 18.17% | 696,084 | Mar 31, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 9.52% | 0.06% | 4,878,000 | - | - | 39,853,260 | Mar 31, 2024 |
| POLYMER CAPITAL MANAGEMENT (HK) LTD | 0.04% | 0.05% | 21,906 | 21,906 | 100.00% | 178,972 | Mar 31, 2024 |
| PROFUND ADVISORS LLC | 0.25% | 0.04% | 126,250 | 126,250 | 100.00% | 1,031,463 | Mar 31, 2024 |
| MARATHON TRADING INVESTMENT MANAGEMENT LLC | 0.13% | 0.04% | 64,000 | 64,000 | 100.00% | 522,880 | Mar 31, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 1.05% | 0.04% | 535,342 | 535,342 | 100.00% | 4,373,744 | Mar 31, 2024 |
| TREXQUANT INVESTMENT LP | 0.44% | 0.04% | 224,487 | 224,487 | 100.00% | 1,834,059 | Mar 31, 2024 |
The largest C4 Therapeutics shareholder by % of total assets is LYNX1 CAPITAL MANAGEMENT LP. The company owns 3.63M shares of C4 Therapeutics (CCCC), representing 7.70% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STATE STREET CORP | 13.97% | 0.00% | 7,153,280 | 6,997,907 | 4503.94% | 58,442,298 | Mar 31, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.80% | 3.26% | 1,435,931 | 1,435,931 | 100.00% | 11,731,556 | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 2.56% | 0.02% | 1,312,200 | 1,239,500 | 1704.95% | 10,720,674 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 2.29% | 0.02% | 1,171,840 | 1,171,840 | 100.00% | 9,573,933 | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | 2.50% | 0.00% | 1,281,242 | 1,167,729 | 1028.72% | 10,467,747 | Mar 31, 2024 |
| VANGUARD GROUP INC | 5.70% | 0.00% | 2,920,028 | 920,627 | 46.05% | 23,856,629 | Mar 31, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 1.63% | 0.03% | 833,681 | 833,681 | 100.00% | 6,811,174 | Mar 31, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | 4.76% | 0.03% | 2,435,380 | 731,111 | 42.90% | 19,897,055 | Mar 31, 2024 |
| CITIGROUP INC | 1.50% | 0.00% | 770,728 | 635,255 | 468.92% | 6,296,848 | Mar 31, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 4.80% | 1.49% | 2,458,996 | 623,000 | 33.93% | 20,089,997 | Mar 31, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 1.05% | 0.04% | 535,342 | 535,342 | 100.00% | 4,373,744 | Mar 31, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 1.23% | 0.00% | 632,091 | 516,583 | 447.23% | 5,164,184 | Mar 31, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 7.10% | 7.70% | 3,634,662 | 500,266 | 15.96% | 29,695,189 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.95% | 0.00% | 487,651 | 487,651 | 100.00% | 3,984,108 | Mar 31, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | 1.49% | 0.04% | 764,862 | 453,485 | 145.64% | 6,248,923 | Mar 31, 2024 |
| UBS GROUP AG | 1.36% | 0.00% | 696,677 | 418,302 | 150.27% | 5,691,851 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.72% | 0.00% | 366,600 | 366,600 | 100.00% | 2,995,122 | Mar 31, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.76% | 0.01% | 388,193 | 361,103 | 1332.98% | 3,171,537 | Mar 31, 2024 |
| ATOM INVESTORS LP | 0.62% | 0.32% | 316,246 | 316,246 | 100.00% | 2,583,730 | Mar 31, 2024 |
| MORGAN STANLEY | 1.00% | 0.00% | 514,183 | 308,842 | 150.40% | 4,200,875 | Mar 31, 2024 |
As of Mar 31 2024, C4 Therapeutics's largest institutional buyer is STATE STREET CORP. The company purchased 7.00M stocks of CCCC, valued at $58.44M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| WASATCH ADVISORS LP | 8.45% | 0.18% | 4,328,479 | -2,810,470 | -39.37% | 35,363,673 | Mar 31, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 1.77% | 0.02% | 906,472 | -1,054,887 | -53.78% | 7,405,876 | Mar 31, 2024 |
| MARSHALL WACE, LLP | 0.29% | 0.00% | 146,644 | -976,417 | -86.94% | 1,198,082 | Mar 31, 2024 |
| BLACKROCK INC. | 1.77% | 0.00% | 905,006 | -898,427 | -49.82% | 7,393,899 | Mar 31, 2024 |
| ARROWMARK COLORADO HOLDINGS LLC | 2.52% | 0.12% | 1,291,939 | -845,442 | -39.55% | 10,555,142 | Mar 31, 2024 |
| INVESCO LTD. | 0.08% | 0.00% | 38,536 | -653,546 | -94.43% | 314,839 | Mar 31, 2024 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 2.23% | 0.75% | 1,142,210 | -500,000 | -30.45% | 9,331,856 | Mar 31, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.13% | 0.00% | 2,115,477 | -443,003 | -17.32% | 17,284,000 | Mar 31, 2024 |
| COMMODORE CAPITAL LP | 6.66% | 1.86% | 3,410,384 | -389,616 | -10.25% | 27,862,837 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 1.12% | 0.00% | 575,131 | -157,014 | -21.45% | 4,698,820 | Mar 31, 2024 |
| AQR CAPITAL MANAGEMENT LLC | - | - | - | -148,610 | -100.00% | - | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.04% | 0.00% | 21,993 | -147,423 | -87.02% | 179,000 | Mar 31, 2024 |
| JANE STREET GROUP, LLC | 0.11% | 0.00% | 54,114 | -144,557 | -72.76% | 442,111 | Mar 31, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | - | - | - | -102,379 | -100.00% | - | Mar 31, 2024 |
| RAYMOND JAMES & ASSOCIATES | - | - | - | -100,984 | -100.00% | - | Mar 31, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | - | - | - | -100,370 | -100.00% | - | Mar 31, 2024 |
| BANK OF MONTREAL /CAN/ | - | - | - | -76,800 | -100.00% | - | Mar 31, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.10% | 0.01% | 49,000 | -75,000 | -60.48% | 400,330 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.30% | 0.00% | 154,500 | -58,400 | -27.43% | 1,262,265 | Mar 31, 2024 |
| 683 CAPITAL MANAGEMENT, LLC | - | - | - | -55,602 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, C4 Therapeutics's biggest institutional seller is WASATCH ADVISORS LP. The company sold -2.81M shares of CCCC, valued at $35.36M.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.80% | 3.26% | 1,435,931 | 1,435,931 | 100.00% | 11,731,556 | Mar 31, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 1.63% | 0.03% | 833,681 | 833,681 | 100.00% | 6,811,174 | Mar 31, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 1.05% | 0.04% | 535,342 | 535,342 | 100.00% | 4,373,744 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.95% | 0.00% | 487,651 | 487,651 | 100.00% | 3,984,108 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.72% | 0.00% | 366,600 | 366,600 | 100.00% | 2,995,122 | Mar 31, 2024 |
| ATOM INVESTORS LP | 0.62% | 0.32% | 316,246 | 316,246 | 100.00% | 2,583,730 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.50% | 0.00% | 257,800 | 257,800 | 100.00% | 2,106,226 | Mar 31, 2024 |
| TREXQUANT INVESTMENT LP | 0.44% | 0.04% | 224,487 | 224,487 | 100.00% | 1,834,059 | Mar 31, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.38% | 0.00% | 197,109 | 197,109 | 100.00% | 1,610,380 | Mar 31, 2024 |
| PROFUND ADVISORS LLC | 0.25% | 0.04% | 126,250 | 126,250 | 100.00% | 1,031,463 | Mar 31, 2024 |
| JUMP FINANCIAL, LLC | 0.23% | 0.03% | 116,507 | 116,507 | 100.00% | 951,862 | Mar 31, 2024 |
| ENGINEERS GATE MANAGER LP | 0.20% | 0.02% | 104,367 | 104,367 | 100.00% | 852,678 | Mar 31, 2024 |
| SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 0.18% | 0.02% | 91,127 | 91,127 | 100.00% | 744,508 | Mar 31, 2024 |
| CAPITAL FUND MANAGEMENT S.A. | 0.15% | 0.00% | 76,791 | 76,791 | 100.00% | 627,382 | Mar 31, 2024 |
| QUEST PARTNERS LLC | 0.13% | 0.09% | 64,001 | 64,001 | 100.00% | 522,888 | Mar 31, 2024 |
| MARATHON TRADING INVESTMENT MANAGEMENT LLC | 0.13% | 0.04% | 64,000 | 64,000 | 100.00% | 522,880 | Mar 31, 2024 |
| WALLEYE CAPITAL LLC | 0.10% | 0.00% | 52,304 | 52,304 | 100.00% | 427,324 | Mar 31, 2024 |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 0.10% | 0.02% | 51,365 | 51,365 | 100.00% | 419,652 | Mar 31, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.10% | 0.03% | 48,763 | 48,763 | 100.00% | 398,000 | Mar 31, 2024 |
| GRAHAM CAPITAL MANAGEMENT, L.P. | 0.09% | 0.01% | 47,449 | 47,449 | 100.00% | 387,658 | Mar 31, 2024 |
| FOX RUN MANAGEMENT, L.L.C. | 0.08% | 0.07% | 41,732 | 41,732 | 100.00% | 340,950 | Mar 31, 2024 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 0.08% | 0.00% | 41,445 | 41,445 | 100.00% | 259,922 | Mar 31, 2024 |
| E FUND MANAGEMENT CO., LTD. | 0.08% | 0.02% | 39,396 | 39,396 | 100.00% | 321,865 | Mar 31, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.08% | 0.00% | 39,002 | 39,002 | 100.00% | 319,000 | Mar 31, 2024 |
| WALLEYE CAPITAL LLC | 0.07% | 0.00% | 34,400 | 34,400 | 100.00% | 281,048 | Mar 31, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 0.06% | 0.00% | 28,590 | 28,590 | 100.00% | 233,580 | Mar 31, 2024 |
| ENTRYPOINT CAPITAL, LLC | 0.06% | 0.21% | 28,516 | 28,516 | 100.00% | 232,976 | Mar 31, 2024 |
| FARALLON CAPITAL MANAGEMENT LLC | 0.05% | 0.00% | 28,000 | 28,000 | 100.00% | 228,760 | Mar 31, 2024 |
| WALLEYE TRADING LLC | 0.05% | 0.00% | 24,794 | 24,794 | 100.00% | 202,567 | Mar 31, 2024 |
| POLYMER CAPITAL MANAGEMENT (HK) LTD | 0.04% | 0.05% | 21,906 | 21,906 | 100.00% | 178,972 | Mar 31, 2024 |
| CAXTON ASSOCIATES LP | 0.04% | 0.01% | 21,002 | 21,002 | 100.00% | 171,586 | Mar 31, 2024 |
| STIFEL FINANCIAL CORP | 0.04% | 0.00% | 20,012 | 20,012 | 100.00% | 163,496 | Mar 31, 2024 |
| LMR PARTNERS LLP | 0.04% | 0.00% | 19,563 | 19,563 | 100.00% | 159,830 | Mar 31, 2024 |
| OCCUDO QUANTITATIVE STRATEGIES LP | 0.04% | 0.03% | 18,317 | 18,317 | 100.00% | 149,650 | Mar 31, 2024 |
| BREVAN HOWARD CAPITAL MANAGEMENT LP | 0.03% | 0.00% | 15,526 | 15,526 | 100.00% | 126,847 | Mar 31, 2024 |
| ENTROPY TECHNOLOGIES, LP | 0.03% | 0.01% | 15,391 | 15,391 | 100.00% | 125,744 | Mar 31, 2024 |
| WALLEYE CAPITAL LLC | 0.03% | 0.00% | 14,900 | 14,900 | 100.00% | 121,733 | Mar 31, 2024 |
| MACQUARIE GROUP LTD | 0.01% | - | 4,009 | 4,009 | 100.00% | 33 | Mar 31, 2024 |
| PACER ADVISORS, INC. | 0.01% | 0.00% | 3,929 | 3,929 | 100.00% | 32,100 | Mar 31, 2024 |
| WALLEYE TRADING LLC | 0.00% | - | 2,200 | 2,200 | 100.00% | 17,974 | Mar 31, 2024 |
| AQUATIC CAPITAL MANAGEMENT LLC | 0.00% | 0.00% | 1,400 | 1,400 | 100.00% | 11,438 | Mar 31, 2024 |
| PISCATAQUA SAVINGS BANK | 0.00% | 0.00% | 600 | 600 | 100.00% | 4,902,000 | Mar 31, 2024 |
| US BANCORP \DE\ | 0.00% | - | 39 | 39 | 100.00% | 319 | Mar 31, 2024 |
C4 Therapeutics's largest new institutional shareholder by number of shares is SILVERARC CAPITAL MANAGEMENT, LLC, purchased 1.44M shares, valued at $11.73M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| AQR CAPITAL MANAGEMENT LLC | - | - | - | -148,610 | -100.00% | - | Mar 31, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | - | - | - | -102,379 | -100.00% | - | Mar 31, 2024 |
| RAYMOND JAMES & ASSOCIATES | - | - | - | -100,984 | -100.00% | - | Mar 31, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | - | - | - | -100,370 | -100.00% | - | Mar 31, 2024 |
| BANK OF MONTREAL /CAN/ | - | - | - | -76,800 | -100.00% | - | Mar 31, 2024 |
| 683 CAPITAL MANAGEMENT, LLC | - | - | - | -55,602 | -100.00% | - | Mar 31, 2024 |
| B. METZLER SEEL. SOHN & CO. AG | - | - | - | -49,037 | -100.00% | - | Mar 31, 2024 |
| CORNERCAP INVESTMENT COUNSEL INC | - | - | - | -46,286 | -100.00% | - | Mar 31, 2024 |
| HSBC HOLDINGS PLC | - | - | - | -30,200 | -100.00% | - | Mar 31, 2024 |
| ALGERT GLOBAL LLC | - | - | - | -27,960 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -25,000 | -100.00% | - | Mar 31, 2024 |
| CRESSET ASSET MANAGEMENT, LLC | - | - | - | -25,000 | -100.00% | - | Mar 31, 2024 |
| LIGHTHOUSE INVESTMENT PARTNERS, LLC | - | - | - | -21,981 | -100.00% | - | Mar 31, 2024 |
| XTX TOPCO LTD | - | - | - | -21,203 | -100.00% | - | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | - | - | - | -20,682 | -100.00% | - | Mar 31, 2024 |
| Y-INTERCEPT (HONG KONG) LTD | - | - | - | -18,823 | -100.00% | - | Mar 31, 2024 |
| MIRABELLA FINANCIAL SERVICES LLP | - | - | - | -18,400 | -100.00% | - | Mar 31, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | - | - | - | -17,749 | -100.00% | - | Mar 31, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | - | - | - | -13,400 | -100.00% | - | Mar 31, 2024 |
| LAZARD ASSET MANAGEMENT LLC | - | - | - | -12,375 | -100.00% | - | Mar 31, 2024 |
| SHERBROOKE PARK ADVISERS LLC | - | - | - | -11,131 | -100.00% | - | Mar 31, 2024 |
| CUTLER GROUP LLC / CA | - | - | - | -10,600 | -100.00% | - | Mar 31, 2024 |
| SHAY CAPITAL LLC | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
| FNY INVESTMENT ADVISERS, LLC | - | - | - | -8,800 | -100.00% | - | Mar 31, 2024 |
| HEADLANDS TECHNOLOGIES LLC | - | - | - | -6,880 | -100.00% | - | Mar 31, 2024 |
| POINT72 ASIA (SINGAPORE) PTE. LTD. | - | - | - | -3,928 | -100.00% | - | Mar 31, 2024 |
| FAIRFIELD, BUSH & CO. | - | - | - | -200 | -100.00% | - | Mar 31, 2024 |
C4 Therapeutics's largest sold out institutional shareholder by shares sold is AQR CAPITAL MANAGEMENT LLC, sold -0.15M shares, valued at -, as of undefined.
C4 Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Clough Global Equity Fund | 1.43% | 88,500 | - | - | Jan 31, 2024 |
| Clough Global Opportunities Fund | 0.41% | 161,281 | - | - | Jan 31, 2024 |
| Clough Funds Trust | 0.34% | 14,000 | - | - | Jan 31, 2023 |
| WASATCH FUNDS TRUST | 0.30% | 2,816,041 | -1,870,419 | -39.91% | Mar 31, 2024 |
| MERIDIAN FUND INC | 0.27% | 953,906 | -203,700 | -17.60% | Dec 29, 2023 |
| CORNERCAP GROUP OF FUNDS /VA/ | 0.14% | 9,815 | - | - | Sep 30, 2022 |
| VANGUARD EXPLORER FUND | 0.13% | 1,651,861 | - | - | Jan 31, 2024 |
| BlackRock Advantage SMID Cap Fund, Inc. | 0.13% | 24,124 | -632 | -2.55% | Dec 29, 2023 |
| PRUDENTIAL SECTOR FUNDS, INC. | 0.10% | 209,981 | - | - | Feb 29, 2024 |
| T. Rowe Price New Horizons Fund, Inc. | 0.09% | 1,406,070 | -357,986 | -20.29% | Dec 31, 2023 |
| ROYCE MICRO-CAP TRUST, INC. | 0.09% | 48,135 | 42,235 | 715.85% | Dec 31, 2023 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.08% | 381,492 | - | - | Dec 31, 2023 |
| BlackRock Health Sciences Trust II | 0.07% | 201,293 | - | - | Dec 31, 2023 |
| VANGUARD VALLEY FORGE FUNDS | 0.06% | 31,822 | - | - | Dec 31, 2023 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 0.06% | 468,657 | - | - | Dec 31, 2023 |
| BRIDGEWAY FUNDS INC | 0.05% | 124,000 | -25,000 | -16.78% | Dec 29, 2023 |
| Vericimetry Funds | 0.05% | 5,070 | - | - | Dec 31, 2023 |
| PRUDENTIAL JENNISON BLEND FUND, INC. | 0.04% | 26,048 | - | - | Feb 29, 2024 |
| Federated Hermes MDT Series | 0.03% | 63,459 | - | - | Jan 31, 2024 |
| T. Rowe Price Quantitative Management Funds, Inc. | 0.02% | 75,400 | - | - | Dec 31, 2023 |
| Humankind Benefit Corp | 0.02% | 439 | - | - | Dec 31, 2023 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 6,192 | - | - | Dec 31, 2023 |
| T. Rowe Price Equity Series, Inc. | 0.01% | 21,403 | - | - | Dec 31, 2023 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.01% | 591,714 | - | - | Dec 31, 2023 |
| Fidelity Commonwealth Trust II | 0.01% | 74,120 | 40,612 | 121.20% | Aug 31, 2023 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 65,317 | - | - | Dec 31, 2023 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 579,281 | - | - | Feb 29, 2024 |
| ETFis Series Trust I | 0.01% | 12,350 | - | - | Jan 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED FUND | 0.01% | 86,239 | - | - | Dec 31, 2023 |
| FIDELITY ADVISOR SERIES VII | 0.01% | 69,700 | - | - | Jan 31, 2024 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.01% | 649,186 | 592,949 | 1054.38% | Jan 31, 2024 |
| AIM EQUITY FUNDS (INVESCO EQUITY FUNDS) | 0.01% | 104,040 | - | - | Jan 31, 2024 |
| VANGUARD INDEX FUNDS | 0.01% | 2,577,639 | 729,065 | 39.44% | Dec 31, 2023 |
| Harbor ETF Trust | 0.00% | 23,300 | 198 | 0.86% | Jan 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.00% | 15,612 | - | - | Feb 29, 2024 |
| VANGUARD QUANTITATIVE FUNDS | 0.00% | 41,400 | 3,600 | 9.52% | Dec 31, 2023 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 970 | - | - | Dec 31, 2023 |
| FIDELITY MT VERNON STREET TRUST | 0.00% | 105,714 | - | - | Feb 29, 2024 |
| DRIEHAUS MUTUAL FUNDS | 0.00% | 27,203 | - | - | Dec 29, 2023 |
| ALPS ETF Trust | 0.00% | 30,916 | - | - | Feb 29, 2024 |
| NEUBERGER BERMAN EQUITY FUNDS | 0.00% | 23,991 | - | - | Feb 29, 2024 |
| HARBOR FUNDS | 0.00% | 54,762 | -572 | -1.03% | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 6,367 | - | - | Dec 31, 2023 |
| Brinker Capital Destinations Trust | 0.00% | 95,550 | - | - | Feb 29, 2024 |
| AIM COUNSELOR SERIES TRUST (INVESCO COUNSELOR SERIES TRUST) | 0.00% | 311,185 | - | - | Feb 29, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 237,802 | 8,090 | 3.52% | Feb 29, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 2,962 | - | - | Dec 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 233,668 | -122,511 | -34.40% | Feb 29, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 13,238 | -1,515 | -10.27% | Mar 31, 2024 |
| JANUS INVESTMENT FUND | 0.00% | 335,365 | - | - | Dec 31, 2023 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 27,453 | - | - | Dec 31, 2023 |
| Direxion Shares ETF Trust | 0.00% | 139,285 | - | - | Jan 31, 2024 |
| MML SERIES INVESTMENT FUND | 0.00% | 6,851 | - | - | Dec 31, 2023 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 12,400 | - | - | Feb 29, 2024 |
| BlackRock ETF Trust | 0.00% | 610 | - | - | Jan 31, 2024 |
| Dimensional ETF Trust | 0.00% | 282,498 | 257,422 | 1026.57% | Jan 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 16,458 | - | - | Dec 31, 2023 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 45,550 | 11,475 | 33.68% | Feb 29, 2024 |
| VANGUARD HORIZON FUNDS | 0.00% | 8,027 | - | - | Dec 31, 2023 |
| RBB FUND, INC. | 0.00% | 33,996 | - | - | Feb 29, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 49,047 | - | - | Dec 31, 2023 |
| NORTHWESTERN MUTUAL SERIES FUND INC | 0.00% | 41,400 | - | - | Dec 31, 2023 |
| OHIO NATIONAL FUND INC | 0.00% | 6,485 | - | - | Dec 31, 2023 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,389 | - | - | Dec 31, 2023 |
| Trust for Advised Portfolios | 0.00% | 4,903 | - | - | Dec 31, 2023 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 2,283 | -42,472 | -94.90% | Dec 31, 2023 |
| VANGUARD WORLD FUND | 0.00% | 39,029 | - | - | Feb 29, 2024 |
| FLEXSHARES TRUST | 0.00% | 12,351 | - | - | Jan 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 367,861 | - | - | Feb 29, 2024 |
| Victory Portfolios II | 0.00% | 7,482 | - | - | Dec 31, 2023 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 10,300 | - | - | Dec 31, 2023 |
| Forethought Variable Insurance Trust | 0.00% | 435 | - | - | Dec 29, 2023 |
| GOLDMAN SACHS TRUST | 0.00% | 15,247 | - | - | Feb 29, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 387 | - | - | Dec 31, 2023 |
| Guggenheim Active Allocation Fund | 0.00% | 460 | - | - | Feb 29, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 152,164 | - | - | Feb 29, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 76,942 | 52,407 | 213.60% | Jan 31, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 18,639 | - | - | Jan 31, 2024 |
| ProFunds | 0.00% | 533 | - | - | Jan 31, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 169,023 | -5,160 | -2.96% | Dec 31, 2023 |
| RUSSELL INVESTMENT FUNDS | 0.00% | 3,528 | - | - | Dec 31, 2023 |
| VALIC Co I | 0.00% | 15,482 | - | - | Feb 29, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 4,328 | - | - | Dec 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 6,373 | 6,134 | 2566.53% | Jan 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 192 | - | - | Dec 31, 2023 |
| PENN SERIES FUNDS INC | 0.00% | 1,300 | - | - | Dec 29, 2023 |
| SPDR SERIES TRUST | 0.00% | 1,716,867 | - | - | Dec 31, 2023 |
| MORGAN STANLEY INSTITUTIONAL FUND INC | 0.00% | 1,580 | - | - | Dec 31, 2023 |
| RYDEX VARIABLE TRUST | 0.00% | 25 | - | - | Dec 31, 2023 |
| HC CAPITAL TRUST | 0.00% | 585 | - | - | Dec 31, 2023 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 20,231 | - | - | Dec 31, 2023 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,683 | - | - | Feb 29, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 35,100 | - | - | Dec 31, 2023 |
| SUNAMERICA SERIES TRUST | 0.00% | 4,820 | - | - | Jan 31, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 4,341 | - | - | Jan 31, 2024 |
| Fidelity Rutland Square Trust II | 0.00% | 16,000 | - | - | Feb 29, 2024 |
| EQ ADVISORS TRUST | 0.00% | 14,895 | 6,305 | 73.40% | Dec 31, 2023 |
| PROSHARES TRUST | 0.00% | 3,138 | - | - | Feb 29, 2024 |
| Franklin Alternative Strategies Funds | 0.00% | 6,325 | - | - | Feb 29, 2024 |
| COLUMBIA FUNDS SERIES TRUST I | 0.00% | 54,250 | - | - | Feb 29, 2024 |
C4 Therapeutics's largest mutual fund holder by % of total assets is "Clough Global Equity Fund", owning 88.50K shares, compromising 1.43% of its total assets.
C4 Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 109 | 21.11% |
| 31 Dec, 23 | 90 | 12.50% |
| 30 Sep, 23 | 80 | -15.79% |
| 30 Jun, 23 | 95 | -17.39% |
| 31 Mar, 23 | 115 | 3.60% |
| 31 Dec, 22 | 111 | 0.91% |
| 30 Sep, 22 | 110 | - |
| 30 Jun, 22 | 110 | -12.00% |
| 31 Mar, 22 | 125 | 6.84% |
| 31 Dec, 21 | 117 | 4.46% |
| 30 Sep, 21 | 112 | 5.66% |
| 30 Jun, 21 | 106 | 29.27% |
| 31 Mar, 21 | 82 | 9.33% |
| 31 Dec, 20 | 75 | - |
As of 31 Mar 24, 109 institutions are holding C4 Therapeutics's shares, representing an increase of 21.11% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 57,968,590 | 26.55% |
| 31 Dec, 23 | 45,805,468 | 33.19% |
| 30 Sep, 23 | 34,391,356 | 1.51% |
| 30 Jun, 23 | 33,878,897 | -8.49% |
| 31 Mar, 23 | 37,021,715 | -5.13% |
| 31 Dec, 22 | 39,025,432 | -0.67% |
| 30 Sep, 22 | 39,287,502 | -0.01% |
| 30 Jun, 22 | 39,289,994 | 5.66% |
| 31 Mar, 22 | 37,185,247 | 3.82% |
| 31 Dec, 21 | 35,815,851 | 3.95% |
| 30 Sep, 21 | 34,454,438 | 7.93% |
| 30 Jun, 21 | 31,921,953 | 27.22% |
| 31 Mar, 21 | 25,092,727 | 10.51% |
| 31 Dec, 20 | 22,706,751 | - |
C4 Therapeutics (CCCC) has 57.97M shares outstanding as of 31 Mar 24, up 26.55% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 113.18% | 1.31% |
| 31 Dec, 23 | 93.08% | 1.89% |
| 30 Sep, 23 | 70.10% | 1.47% |
| 30 Jun, 23 | 69.09% | 1.21% |
| 31 Mar, 23 | 75.50% | 1.18% |
| 31 Dec, 22 | 79.87% | 1.24% |
| 30 Sep, 22 | 80.31% | 1.24% |
| 30 Jun, 22 | 80.47% | 1.38% |
| 31 Mar, 22 | 76.30% | 1.40% |
| 31 Dec, 21 | 73.86% | 1.46% |
| 30 Sep, 21 | 71.05% | 1.34% |
| 30 Jun, 21 | 72.79% | 2.15% |
| 31 Mar, 21 | 58.24% | 1.88% |
| 31 Dec, 20 | 55.70% | - |
As of 31 Mar 24, C4 Therapeutics is held by 113.18% institutional shareholders, representing a 1.31% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 69 | 27.78% |
| 31 Dec, 23 | 54 | 42.11% |
| 30 Sep, 23 | 38 | -26.92% |
| 30 Jun, 23 | 52 | -17.46% |
| 31 Mar, 23 | 63 | 14.55% |
| 31 Dec, 22 | 55 | -11.29% |
| 30 Sep, 22 | 62 | -3.13% |
| 30 Jun, 22 | 64 | -11.11% |
| 31 Mar, 22 | 72 | 14.29% |
| 31 Dec, 21 | 63 | -11.27% |
| 30 Sep, 21 | 71 | -10.13% |
| 30 Jun, 21 | 79 | 75.56% |
| 31 Mar, 21 | 45 | -40.00% |
| 31 Dec, 20 | 75 | - |
69 institutional shareholders have increased their position in CCCC stock as of 31 Mar 24 compared to 54 in the previous quarter (a 27.78% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 25 | - |
| 31 Dec, 23 | 25 | -16.67% |
| 30 Sep, 23 | 30 | -11.76% |
| 30 Jun, 23 | 34 | -2.86% |
| 31 Mar, 23 | 35 | 9.38% |
| 31 Dec, 22 | 32 | 3.23% |
| 30 Sep, 22 | 31 | -3.13% |
| 30 Jun, 22 | 32 | 6.67% |
| 31 Mar, 22 | 30 | -6.25% |
| 31 Dec, 21 | 32 | 60.00% |
| 30 Sep, 21 | 20 | 53.85% |
| 30 Jun, 21 | 13 | -38.10% |
| 31 Mar, 21 | 21 | - |
| 31 Dec, 20 | - | - |
25 institutional shareholders have reduced their position in CCCC stock as of 31 Mar 24 compared to 25 in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 109 | 21.11% | 57,968,590 | 26.55% | 113.18% | 1.31% | 69 | 27.78% | 25 | - |
| 31 Dec, 23 | 90 | 12.50% | 45,805,468 | 33.19% | 93.08% | 1.89% | 54 | 42.11% | 25 | -16.67% |
| 30 Sep, 23 | 80 | -15.79% | 34,391,356 | 1.51% | 70.10% | 1.47% | 38 | -26.92% | 30 | -11.76% |
| 30 Jun, 23 | 95 | -17.39% | 33,878,897 | -8.49% | 69.09% | 1.21% | 52 | -17.46% | 34 | -2.86% |
| 31 Mar, 23 | 115 | 3.60% | 37,021,715 | -5.13% | 75.50% | 1.18% | 63 | 14.55% | 35 | 9.38% |
| 31 Dec, 22 | 111 | 0.91% | 39,025,432 | -0.67% | 79.87% | 1.24% | 55 | -11.29% | 32 | 3.23% |
| 30 Sep, 22 | 110 | - | 39,287,502 | -0.01% | 80.31% | 1.24% | 62 | -3.13% | 31 | -3.13% |
| 30 Jun, 22 | 110 | -12.00% | 39,289,994 | 5.66% | 80.47% | 1.38% | 64 | -11.11% | 32 | 6.67% |
| 31 Mar, 22 | 125 | 6.84% | 37,185,247 | 3.82% | 76.30% | 1.40% | 72 | 14.29% | 30 | -6.25% |
| 31 Dec, 21 | 117 | 4.46% | 35,815,851 | 3.95% | 73.86% | 1.46% | 63 | -11.27% | 32 | 60.00% |
| 30 Sep, 21 | 112 | 5.66% | 34,454,438 | 7.93% | 71.05% | 1.34% | 71 | -10.13% | 20 | 53.85% |
| 30 Jun, 21 | 106 | 29.27% | 31,921,953 | 27.22% | 72.79% | 2.15% | 79 | 75.56% | 13 | -38.10% |
| 31 Mar, 21 | 82 | 9.33% | 25,092,727 | 10.51% | 58.24% | 1.88% | 45 | -40.00% | 21 | - |
| 31 Dec, 20 | 75 | - | 22,706,751 | - | 55.70% | - | 75 | - | - | - |
C4 Therapeutics Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of C4 Therapeutics's stock was made by Boyle Scott N on Mar 08 2024, selling 115,000 shares at $33.23 per share (valued at $3.82M).
C4 Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 3 | - | - |
| Q1 2024 | 25 | 14 | 178.57% |
| Q4 2023 | 4 | - | - |
| Q3 2023 | 18 | 18 | 100.00% |
| Q2 2023 | 9 | - | - |
| Q1 2023 | 25 | 16 | 156.25% |
| Q4 2022 | 5 | 2 | 250.00% |
| Q3 2022 | 6 | 3 | 200.00% |
| Q2 2022 | 16 | 12 | 133.33% |
| Q1 2022 | 19 | 10 | 190.00% |
| Q4 2021 | 11 | 12 | 91.67% |
| Q3 2021 | 9 | 43 | 20.93% |
| Q2 2021 | 20 | 7 | 285.71% |
| Q1 2021 | 11 | 6 | 183.33% |
| Q4 2020 | 29 | 40 | 72.50% |
3 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by C4 Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | - | - |
| Q1 2024 | - | - | - |
| Q4 2023 | - | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | - | - | - |
| Q1 2023 | 1 | - | - |
| Q4 2022 | - | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | 1 | - | - |
| Q1 2022 | - | 2 | - |
| Q4 2021 | - | 6 | - |
| Q3 2021 | - | 39 | - |
| Q2 2021 | - | 4 | - |
| Q1 2021 | - | - | - |
| Q4 2020 | 3 | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of C4 Therapeutics's stocks.
C4 Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| RZLT | Rezolute, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| ARVN | Arvinas, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| IPSC | Century Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| CGEM | Cullinan Oncology, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| STTK | Shattuck Labs, Inc. |
CCCC Ownership FAQ
Who Owns C4 Therapeutics?
C4 Therapeutics is owned by institutional shareholders (113.18%), insiders (11.75%), and public (-24.93%). The largest institutional shareholder of C4 Therapeutics is STATE STREET CORP (13.97% of total shares) and the top mutual fund owner is Clough Global Equity Fund (1.43% of total shares).
Who are the major institutional shareholders of C4 Therapeutics?
C4 Therapeutics's major institutional shareholders are STATE STREET CORP, RA CAPITAL MANAGEMENT, L.P., WASATCH ADVISORS LP, LYNX1 CAPITAL MANAGEMENT LP, and COMMODORE CAPITAL LP. The top five shareholders own together 45.70% of the company's share outstanding.
How many C4 Therapeutics shareholders are there?
As of Mar 2024, there are 109 institutional shareholders of C4 Therapeutics.
What percentage of C4 Therapeutics is owned by STATE STREET CORP?
STATE STREET CORP owns 7.15M shares of C4 Therapeutics, representing 13.97% of the company's total shares outstanding, valued at $58.44M (as of Mar 2024).
What percentage of C4 Therapeutics is owned by RA CAPITAL MANAGEMENT, L.P?
As of Mar 2024, RA CAPITAL MANAGEMENT, L.P holds 4.88M shares of C4 Therapeutics (CCCC), compromising 9.52% of the company, valued at $39.85M.
What percentage of C4 Therapeutics is owned by WASATCH ADVISORS LP?
WASATCH ADVISORS LP is the third largest holder of C4 Therapeutics. The company owns 4.33M of the company's shares outstanding (worth $35.36M).